Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-004888-31
    Sponsor's Protocol Code Number:OXN3508
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-10-03
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2013-004888-31
    A.3Full title of the trial
    A randomised, double-blind, double-dummy, cross-over multicenter study to demonstrate equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy.
    Estudio multicéntrico con grupos cruzados, aleatorizado, doble ciego y doble enmascaramiento para demostrar la equivalencia en la eficacia analgésica y función intestinal de dosis equivalentes de oxicodona de 120 y 160 mg al día, utilizando las presentaciones de comprimidos de mayor dosis de OXN PR (OXN60/30 mg PR, OXN80/40 mg PR) dos veces al día, en comparación con la dosis idéntica diaria utilizando una combinación de comprimidos de menor dosis en individuos con dolor oncológico y no oncológico que requiere un tratamiento continuo con opiáceos.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study which will show the equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as achieved with the higher OXN PR tablet strengths (OXN60/30 mg PR, OXN80/40 mg PR) twice daily compared to the identical daily dose taken as a combination of lower tablet strengths in subjects with non-cancer or cancer pain that requires around-the-clock opioid therapy.
    Estudio para demostrar la equivalencia en la eficacia analgésica y función intestinal entre tomando oxicodona equivalente de 120 y 160 mg por día utilizando las presentaciones de comprimidos de mayor dosis de OXN PR (OXN60/30 mg PR, OXN80/40 mg PR) dos veces al día, en comparación con la dosis idéntica diaria utilizando una combinación de comprimidos de menor dosis en individuos con dolor oncológico y no oncológico que requiere un tratamiento continuo con opiáceos.
    A.4.1Sponsor's protocol code numberOXN3508
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMundipharma Research GmbH & Co. KG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMundipharma Research GmbH & Co. KG
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMundipharma Research GmbH & Co. KG
    B.5.2Functional name of contact pointClinical trial contact
    B.5.3 Address:
    B.5.3.1Street AddressHoehenstrasse 10
    B.5.3.2Town/ cityLimburg (Lahn)
    B.5.3.3Post code65549
    B.5.3.4CountryGermany
    B.5.4Telephone number+34916307487
    B.5.5Fax number+4964317018453
    B.5.6E-mailbarbara.riechert@mundipharma-rd.eu
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOxycodone/Naloxone 60/30mg prolonged release tablets
    D.3.2Product code OXN 60/30 mg PR
    D.3.4Pharmaceutical form Prolonged-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOXYCODONE HYDROCHLORIDE
    D.3.9.1CAS number 124-90-3
    D.3.9.3Other descriptive nameOXYCODONE HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB03583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.1CAS number 51481-60-8
    D.3.9.3Other descriptive nameNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.4EV Substance CodeSUB03382MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOxycodone/Naloxone 80/40mg prolonged release tablets
    D.3.2Product code OXN 80/40mg PR
    D.3.4Pharmaceutical form Prolonged-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOXYCODONE HYDROCHLORIDE
    D.3.9.1CAS number 124-90-3
    D.3.9.3Other descriptive nameOXYCODONE HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB03583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number80
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.1CAS number 51481-60-8
    D.3.9.3Other descriptive nameNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.4EV Substance CodeSUB03382MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Targinact 10/5mg
    D.2.1.1.2Name of the Marketing Authorisation holderNapp Pharmaceuticals Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Prolonged-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOXYCODONE HYDROCHLORIDE
    D.3.9.1CAS number 124-90-3
    D.3.9.3Other descriptive nameOXYCODONE HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB03583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.1CAS number 51481-60-8
    D.3.9.3Other descriptive nameNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.4EV Substance CodeSUB03382MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Targinact 20/10mg
    D.2.1.1.2Name of the Marketing Authorisation holderNapp Pharmaceuticals Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Prolonged-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOXYCODONE HYDROCHLORIDE
    D.3.9.1CAS number 124-90-3
    D.3.9.3Other descriptive nameOXYCODONE HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB03583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.1CAS number 51481-60-8
    D.3.9.3Other descriptive nameNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.4EV Substance CodeSUB03382MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Targinact 40/20mg
    D.2.1.1.2Name of the Marketing Authorisation holderNapp Pharmaceuticals Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Prolonged-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOXYCODONE HYDROCHLORIDE
    D.3.9.1CAS number 124-90-3
    D.3.9.3Other descriptive nameOXYCODONE HYDROCHLORIDE
    D.3.9.4EV Substance CodeSUB03583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.1CAS number 51481-60-8
    D.3.9.3Other descriptive nameNALOXONE HYDROCHLORIDE DIHYDRATE
    D.3.9.4EV Substance CodeSUB03382MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboProlonged-release tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboProlonged-release tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 3
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboProlonged-release tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 4
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboProlonged-release tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    The intended indication is:
    Chronic severe non malignant pain, chronic severe malignant pain, requiring opioids.
    La indicación que se pretende es:
    Dolor intenso no oncológico/oncológico, que requiere opiáceos
    E.1.1.1Medical condition in easily understood language
    Chronic severe non cancer pain, chronic severe cancer pain, requiring opioids.
    Dolor intenso no oncológico/oncológico, que requiere opiáceos
    E.1.1.2Therapeutic area Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level PT
    E.1.2Classification code 10033371
    E.1.2Term Pain
    E.1.2System Organ Class 10018065 - General disorders and administration site conditions
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Primary objective:
    To demonstrate equivalence between multiple lower strength OXN PR tablets and a single higher strength OXN PR tablet taken at the same overall total daily dose as shown by:
    ? Analgesic efficacy based on the mean of subjects? ?Average Pain over the last 24 hours? at the last 2 visits of each Cross-over Period, as assessed by the Pain Intensity Scale.
    Co-primary objective:
    ? Equivalent bowel function as assessed by the Bowel Function Index (BFI).
    Objetivo principal:
    Demostrar la equivalencia entre varios comprimidos de OXN PR de menor concentración y un solo comprimido de OXN PR de mayor concentración tomados en la misma dosis diaria total, como se demuestra por medio de lo siguiente:
    ?Eficacia analgésica, basada en la media del dolor promedio de los pacientes durante las 24 horas anteriores en las 2 últimas visitas de cada período cruzado, evaluada mediante la Escala de intensidad del dolor.
    E.2.2Secondary objectives of the trial
    Secondary objectives:
    ? To assess analgesic efficacy (each visit) and rescue medication use.
    ? To assess bowel function (each visit) and laxative use.
    ? To assess quality of life based on the EuroQol EQ-5D.
    ? To assess safety profile.
    Objetivos secundarios:
    ?Evaluar la eficacia analgésica (en cada visita) y el uso de medicamentos de rescate.
    ?Evaluar la función intestinal (en cada visita) y el uso de laxantes.
    ?Evaluar la calidad de vida basada en el EuroQol EQ-5D.
    ?Evaluar el perfil de seguridad.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects to be included in the study are those who meet all of the following criteria:
    1. Male or female subjects at least 18 years (females less than one year post-menopausal must have a negative serum or urine pregnancy test prior to the first dose of study treatment, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasoectomised partner).
    2. Subjects receiving WHO step III opioid analgesic medication for the treatment of severe non-malignant or malignant pain in the oxycodone equivalent range of 100 ? 160 mg per day, who could benefit from improved analgesic efficacy, improved tolerability or optimised treatment regimen (e.g. reduction of number of different drugs, less different formulation usage/route of applications).
    3. Documented history of severe non-malignant or malignant pain that will require around-the-clock opioid therapy for a minimum of 6 weeks (OXN60/30 mg PR or OXN80/40 mg PR twice daily).
    4. Subjects must be willing to change/adapt their current opioid analgesic treatment/regimen.
    5. Subjects must be willing and able (e.g. mental and physical condition) to participate in all aspects of the study, including use of medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements as evidenced by providing written, informed consent.
    6. In the Investigator?s opinion the subject?s non-analgesic concomitant medications, including those medications for the treatment of depression are thought to be stable, and will remain stable throughout the Double-blind Phase of the study.
    7. In the Investigator?s opinion the non-opioid analgesic medication dose will remain stable during the Double-blind Phase.
    Los pacientes que se incluirán en el estudio son los que cumplan todos los criterios siguientes:
    1.Pacientes de ambos sexos de al menos 18 años de edad (Las mujeres con menos de un año de menopausia deben tener una prueba de embarazo en suero u orina negativa antes de recibir la primera dosis del tratamiento del estudio, no estar en período de lactancia, y estar dispuestas a utilizar métodos anticonceptivos adecuados y altamente efectivos durante todo el estudio. Un método anticonceptivo muy eficaz se define como aquel que se asocia a una tasa baja de fracasos (es decir, menos del 1 % anual) cuando se utiliza de forma continuada y correcta, como esterilización, implantes, inyectables, anticonceptivos orales combinados, algunos DIU (dispositivos intrauterinos, hormonales), abstinencia sexual o vasectomía de la pareja).
    2.Pacientes que reciben analgésicos en el tercer escalón de la OMS para el tratamiento del dolor intenso no oncológico o oncológico en un intervalo equivalente a oxicodona 100 ? 160 mg al día, que podrían beneficiarse de la mejora de la eficacia analgésica, la mejora de la tolerabilidad o del régimen de tratamiento optimizado (p. ej., reducción del número de fármacos diferentes, menos uso de distintas formulaciones y vías de administración).
    3.Antecedentes documentados de dolores intensos no oncológicos o oncológicos que requerirán tratamiento con opiáceos a lo largo de todo el día durante al menos 6 semanas (OXN60/30 mg PR u OXN80/40 mg PR dos veces al día).
    4.Pacientes dispuestos a cambiar o adaptar su tratamiento/régimen analgésico opioide actual.
    5.Pacientes dispuestos y capaces (mental y físicamente) de participar en todos los aspectos del estudio, incluido el uso del medicamento, la realización de evaluaciones subjetivas, la asistencia a las visitas programadas al centro clínico, la respuesta a los contactos telefónicos y el cumplimiento de los requisitos del protocolo, como se prueba proporcionando por escrito el consentimiento informado.
    6.En opinión del investigador, los medicamentos concomitantes no analgésicos del paciente, incluidos los utilizados para el tratamiento de la depresión, son estables y se mantendrán estables a lo largo de la fase doble ciego del estudio.
    7.En opinión del investigador, la dosis del analgésico no opioide se mantendrá estable durante la fase doble ciego.
    E.4Principal exclusion criteria
    Subjects to be excluded from the study are those who meet any of the following criteria:

    1. Any history of hypersensitivity to oxycodone, naloxone, related products or other ingredients of the study treatment.
    2. Any contraindication to oxycodone, naloxone and other ingredients of the study treatment.
    3. Subjects with any situation in which opioids are contraindicated (e.g. severe respiratory depression with hypoxia and/or hypercapnia, severe chronic obstructive lung disease, paralytic ileus).
    4. Subjects already receiving OXN PR plus additional opioid and being dissatisfied due to unacceptable tolerability of OXN PR.
    5. Active alcohol or drug abuse and/or history of opioid abuse.
    6. Subjects with a positive urine drug test at screening visit 1, which indicates unreported illicit drug use or unreported use of a concomitant medication not required to treat the subjects? medical condition(s).
    7. Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal (e.g. paralytic ileus), or psychiatric disease, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the subject at risk upon exposure to the study treatment or that may confound the analysis and/or interpretation of the study results.
    8. Chronic or intermittent pain that results from Fibromyalgia or Rheumatoid Arthritis.
    9. Subjects with hypothyroidism (non-compensated), Addison`s disease or increase of intracranial pressure.
    10. Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the Investigator?s opinion, may pose a risk of additional CNS depression with opioid study treatment.
    11. Subjects with uncontrolled seizures or convulsive disorder.
    12. Surgery within 2 months prior to the start of the Screening Period, or planned surgery during the Run-in Period and 6-week Double-blind Phase that may affect GI motility or pain.
    13. Subjects presently taking, or who have taken peripheral antagonists (methylnaltrexone, Almivopan) ? 30 days prior to the start of the Screening Period.
    14. Subjects suffering from diarrhoea.
    15. Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (> 3 times the upper limit of normal) or an abnormal total bilirubin and/or creatinine level(s) (> 1.5 times the upper limit of normal), gamma glutamyl transpeptidase (GGT or GGTP) ? 3 times the upper limit of normal.
    16. Subjects presently taking or who have taken monoamine oxidase inhibitors (MAOI) ? 2 weeks prior to the start of the Screening Period.
    17. Subjects who have experienced persistent drug withdrawal symptoms during a previous treatment with OXN PR.

    Additional exclusion criterion for subjects suffering from non-malignant pain:
    18. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period).

    Additional exclusion criteria for subjects suffering from cancer pain:
    19. Subjects with known or suspected unstable brain metastases or spinal cord compression that may require changes in steroid treatment throughout the duration of the study.
    20. Cyclic chemotherapy in the 2 weeks before the screening visit or planned during the study that has shown in the past to significantly influence bowel function. If subjects are having their first cycle of chemotherapy during the 2 weeks before the screening visit or during the study they should be excluded.
    21. Radiotherapy that, in the Investigators opinion, would influence bowel function or pain during the study.
    22. Subjects who have received a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period). Concurrent participation in another clinical trial is not permitted unless long-term survival data will be assessed in an epidemiological study only.
    23. Subjects with an expected life expectancy of less than 3 months and a Karnofsky Performance Scale Index < 40.
    Se excluirá del estudio a los pacientes si cumplen alguno de los siguientes criterios:
    1.Antecedentes de hipersensibilidad a la oxicodona, a la naloxona, a productos relacionados o a otros ingredientes del tratamiento del estudio.
    2.Contraindicaciones a la oxicodona, a la naloxona y a otros ingredientes del tratamiento del estudio.
    3.Cualquier situación en la que los opiáceos estén contraindicados (p. ej., depresión respiratoria grave con hipoxia y/o hipercapnia, neumopatía obstructiva crónica grave o íleo paralítico).
    4.Pacientes que ya están recibiendo OXN PR más un opioide adicional y que no estén satisfechos debido a la tolerabilidad inaceptable de OXN PR.
    5.Alcoholismo o toxicomanía activos y/o antecedentes de abuso de opiáceos.
    6.Pacientes con resultado positivo en la prueba de drogas en orina en la visita 1 de selección, que indica una drogadicción ilícita no declarada o el uso no declarado de un medicamento concomitante que no se requiera para el tratamiento de su afección.
    7.Indicios de enfermedad cardiovascular, renal, hepática, digestiva (p. ej., íleo paralítico) o psiquiátrica clínicamente significativa, según lo determinado por la historia clínica, los análisis clínicos, los resultados del ECG y la exploración física, que supusiera un riesgo para el paciente al exponerse al tratamiento del estudio o que pudiera confundir el análisis y/o la interpretación de los resultados del estudio.
    8.Dolor crónico o intermitente debido a fibromialgia o artritis reumatoide.
    9.Pacientes con hipotiroidismo (no compensado), enfermedad de Addison o aumento de la presión intracraneal.
    10.Pacientes que reciben hipnóticos u otros depresores del sistema nervioso central (SNC) que, en opinión del investigador, puedan representar un riesgo de depresión adicional del SNC por el tratamiento con opiáceos del estudio.
    11.Pacientes con convulsiones o trastorno convulsivo no controlados.
    12.Cirugía en los 2 meses anteriores al inicio del período de selección, o cirugía programada durante el período de pre-inclusión y la fase doble ciego de 6 semanas de duración, que pudiera afectar a la motilidad digestiva o provocar dolor.
    13.Uso actual o anterior de antagonistas periféricos (metilnaltrexona, almivopán) <= 30 días antes del inicio del período de selección.
    14.Pacientes que presentan diarrea
    15.Concentraciones anómalas de aspartato-aminotransferasa (AST, SGOT), alanina-aminotransferasa (ALT, SGPT), fosfatasa alcalina (> 3 veces el límite superior de la normalidad), bilirrubina total y/o creatinina (>1,5 veces el límite superior de la normalidad) o ?-glutamiltransferasa (GGT o GGTP)? 3 veces el límite superior de la normalidad.
    16.Uso actual o anterior de inhibidores de la monoaminooxidasa (IMAO)?2 semanas antes del inicio del período de selección.
    17.Pacientes que han experimentado síntomas persistentes de abstinencia de drogas durante un tratamiento anterior con OXN PR.
    E.5 End points
    E.5.1Primary end point(s)
    Primary Endpoint:
    Analgesic efficacy based on the mean of subjects? ?Average Pain over the last 24 hours? at the last 2 visits of each cross-over Period, as assessed by the Pain Intensity Scale.

    Co-primary Endpoint:
    Equivalent bowel function as assessed by the Bowel Function Index (BFI).
    Variable principal:
    Eficacia analgésica, basada en la media del dolor promedio de los pacientes durante las 24 horas anteriores en las 2 últimas visitas de cada período cruzado, evaluada mediante la Escala de intensidad del dolor.
    Variable co-principal:
    Función intestinal equivalente, evaluada mediante el Índice de función intestinal (Bowel Function Index, BFI).
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoint 'Average Pain over the last 24 hours' and the co-primary endpoint 'BFI? will be derived as the arithmetic mean value of the observed values at Visits 5 and 6 with cross-over period 1, and the arithmetic mean value of the observed values at Visits 8 and 9 with cross-over period 2, respectively
    Variable principal de eficacia:Escala de intensidad del dolor (Escala de valoración numérica, EVN, 0 ? 10) ? «Media del dolor en las últimas 24 horas», según la evaluación en las visitas 5 y 6 y en las visitas 8 y 9.
    E.5.2Secondary end point(s)
    To assess analgesic efficacy (each visit) and rescue medication use.
    To assess bowel function (each visit) and laxative use.
    To assess quality of life based on the EuroQol EQ-5D.
    To assess safety profile.
    Evaluar la eficacia analgésica (en cada visita) y el uso de medicamentos de rescate.
    Evaluar la función intestinal (en cada visita) y el uso de laxantes.
    Evaluar la calidad de vida basada en el EuroQol EQ-5D.
    Evaluar el perfil de seguridad.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Each cross over visit
    Cada visita cruzada
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over Yes
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Open label extension phase
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    doble ciego
    double dummy
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA60
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UPUV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 100
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state60
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After termination of the study subjects should be prescribed registered prolonged release opioids and immediate release opioids for the treatment of breakthrough pain according to the Investigator?s judgement to establish the daily opioid dose needed for continuation of pain treatment. The duration of the consecutive opioid pain treatment is based on the judgement of the Investigator or the subject?s general practitioner.
    Después de la terminación del estudio, se debe prescribir a los pacientes opiáceos registrados de liberación prolongada y opiáceos de liberación inmediata para el tratamiento del dolor intercurrente de acuerdo con el criterio del investigador para establecer la dosis diaria de opiáceos necesaria para continuar el tratamiento del dolor. La duración del tratamiento consecutivo con opiáceos para el dolor se basa en el criterio del investigador o del médico general del paciente.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-11-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-10-27
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2016-08-03
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:09:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA